Effects of alfa glucosidase inhibitors (miglitol, voglibose) on efficacy and safety in type 2 diabetic patients with coronary artery disease.

Effects of alfa glucosidase inhibitors (miglitol, voglibose) on efficacy and safety in type 2 diabetic patients with coronary artery disease. - Clinical study on vascular endothelial function improvement effect using coronary flow reserve (CFR) by alfa GI treatment

Status

Recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000005777

Enrollment

Registered

2011-06-14

Start date

2011-06-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

type 2 diabetes patients with coronary artery disease

Interventions

miglitol 150 mg/day voglibose 0.9 mg/day

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: 1)Type 2 diabetic patients with coronary artery disease. 2)HbA1c <= 10.0%(JDS) and 1,5AG <=14.0 micro g/mL

Exclusion criteria

Exclusion criteria: 1)type 1 diabetes mellitus 2)patients who develops asymptomatic hypoglycemia (hypoglycemia unawareness) or severe hypoglycemia repeatedly. 3)patients who have serious liver disease (AST and/or ALT are more than 100 IU/L) 4)patients who have serious kidney disease (Serum Cr is more than 2.0 mg/dL) 5)patients who have serious cardiac disease (patients who have apparent heartfailure or myocardial infarction within 6 months) 6)patients who have serious pancreatic disease 7)patients with cancer 8)patients with serious infection, serious traumatic injury, perioperative period 9)patients with serious diabetic complications including progressed neuropathy and proliferative retinopathy 10)Patients with serious ketosis, diabetic coma, pre-coma 11)patients who have inflammatory bowel disease, ulcer in bowel, ileus and high risk for ilus 12)patinets with chronic bowel diseases which have probability to induce malabsorption syndrome 13)patients who has the disease which is deteriorated with increase of gas in bowel 14)patients who have history of gastrectomy 15)patients with lactose intolerance 16)heavy alcohol drinker (patients who drink more than 480 mL of Japanese Sake, 2L of beer, 180 mL of whisky, 360 mL of wine, or 360 mL of Shochu per day) 17)patients under steroid treatment 18)patients who are pregnant, hope to be pregnant, or are in lactation period 19)patients who are not applicable to this study judged by the medical doctor

Design outcomes

Primary

Measure	Time frame
Coronary Flow Reserve	—

Secondary

Measure	Time frame
blood glucose, inflammatory marker, Cardiac function	—

Countries

Japan

Contacts

Public ContactHiroyasu Uzui

University of Fukui Faculty of Medical Sciences Division of cardiovascular Medicine

huzui@u-fukui.ac.jp0776-61-3111

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026